Case Report: BARD1 p.Val507Met in two relatives with ER-positive breast cancer: cascade testing and exploratory longitudinal cfDNA dynamics
Abstract
We report two maternally related women with ER-positive breast cancer carrying the germline BARD1 NM_000465.4:c.1519G>A (p.Val507Met) variant. This constitutional variant is currently classified as benign/likely benign and is not presented as causally related to the observed cancers. The study integrated longitudinal clinical follow-up, germline and tumor molecular analyses, targeted family evaluation of 21 biologically related relatives, including genetic testing in 19 relatives, and serial plasma cfDNA monitoring. Longitudinal cfDNA changes were observed during follow-up in both patients; however, these exploratory observations were not interpreted as establishing a quantitative relationship between cfDNA concentration and disease stage or tumor burden. The proband showed rising cfDNA levels during the documented course of metastatic progression, without a variant-specific circulating signal, whereas in the second relative a p.Val507Met-specific signal was detected only in the final available plasma sample before mammographic detection and histopathological confirmation of breast cancer. Because the variant is constitutional, this signal could not establish the presence of tumor-derived ctDNA. These observations generate the hypothesis that sustained increases from individual baseline cfDNA levels may provide a complementary signal prompting earlier clinical assessment or imaging in individuals undergoing longitudinal breast surveillance, particularly in resource-limited settings.
Related
- Examining individual and school-level predictors of positive attitudes towards condom use among adolescents in Tanzania: An exploratory analysis using hierarchical linear modeling
- Exploratory longitudinal monitoring of physiological, hematological, psychological, and irisin responses during an 8-week pre-competition period in elite rhythmic gymnasts
- Longitudinal Circulating Nerve Growth Factor in Pancreatic Ductal Adenocarcinoma: An Exploratory Study of Postoperative Recurrence and First-Line Disease Control
- Disease-related readmission in anti-SRP-positive immune-mediated necrotizing myopathy: Incidence and exploratory associated factors in a retrospective cohort study
- Real-world clinical effectiveness and exploratory longitudinal immunological changes of Efgartigimod in myasthenia gravis: a retrospective study and a single-cell analysis in one patient
BibTeX
@article{melikova2026case,
title = {{Case Report: BARD1 p.Val507Met in two relatives with ER-positive breast cancer: cascade testing and exploratory longitudinal cfDNA dynamics}},
author = {Leylakhanim A. Melikova},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1961175},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1961175},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Case Report: BARD1 p.Val507Met in two relatives with ER-positive breast cancer: cascade testing and exploratory longitudinal cfDNA dynamics
AU - Leylakhanim A. Melikova
PY - 2026
DA - 2026/11/09
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1961175
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1961175
AB - We report two maternally related women with ER-positive breast cancer carrying the germline BARD1 NM_000465.4:c.1519G>A (p.Val507Met) variant. This constitutional variant is currently classified as benign/likely benign and is not presented as causally related to the observed cancers. The study integrated longitudinal clinical follow-up, germline and tumor molecular analyses, targeted family evaluation of 21 biologically related relatives, including genetic testing in 19 relatives, and serial plasma cfDNA monitoring. Longitudinal cfDNA changes were observed during follow-up in both patients; however, these exploratory observations were not interpreted as establishing a quantitative relationship between cfDNA concentration and disease stage or tumor burden. The proband showed rising cfDNA levels during the documented course of metastatic progression, without a variant-specific circulating signal, whereas in the second relative a p.Val507Met-specific signal was detected only in the final available plasma sample before mammographic detection and histopathological confirmation of breast cancer. Because the variant is constitutional, this signal could not establish the presence of tumor-derived ctDNA. These observations generate the hypothesis that sustained increases from individual baseline cfDNA levels may provide a complementary signal prompting earlier clinical assessment or imaging in individuals undergoing longitudinal breast surveillance, particularly in resource-limited settings.
SN - 2234-943X
ER -